Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C

Transfusion

Volumn 48, Issue 2, 2008, Pages 286-294

  Komiya, Yutaka ^b   Katayama, Keiko ^b   Yugi, Hisao ^b   Mizui, Masaaki ^b   Matsukura, Harumichi ^b   Tomoguri, Tetsushi ^b   Miyakawa, Yuzo ^b   Tabuchi, Ayako ^b   Tanaka, Junko ^b   Yoshizawa, Hiroshi ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMPANZEE; CONFIDENCE INTERVAL; GENOTYPE; HEPATITIS B VIRUS; INOCULATION; MALE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; VIREMIA;

ANIMALS; DNA, VIRAL; FEMALE; GENE DOSAGE; GENOTYPE; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; INDICATOR DILUTION TECHNIQUES; MALE; PAN TROGLODYTES; VIREMIA; VIRUS REPLICATION;

EID: 38349163128     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01522.x     Document Type: Article

References (22)

1. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Lancet 1991 338 : 1040 1.
2. Kojima M, Shimizu M, Tsuchimochi T, Koyasu M, Tanaka S, Iizuka H, Tanaka T, Okamoto H, Tsuda F, Miyakawa Y, Mayumi M. Posttransfusion fulminant hepatitis B associated with precore-defective HBV mutants. Vox Sang 1991 60 : 34 9.
3. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low HBV-DNA levels identified in a look back program. Transfusion 2007 47 : 1197 205.
4. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K. HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005 88 : 77 86.
5. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003 43 : 788 98.
6. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
7. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006 36 Suppl 1 : S23 9.
8. Yugi H, Mizui M, Tanaka J, Yoshizawa H. Hepatitis B virus (HBV) screening strategy to ensure the safety of blood for transfusion through a combination of immunological testing and nucleic acid amplification testing - Japanese experience. J Clin Virol 2006 36 Suppl 1 : S56 64.
9. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002 42 : 537 48.
10. Prince AM, Brotman B. Perspectives on hepatitis B studies with chimpanzees. ILAR J 2001 42 : 85 8.
11. Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T, Imai M, Mayumi M, Moritsugu Y. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977 136 : 571 6.
12. Minegishi K, Yoshikawa A, Kishimoto S, Yugi H, Yokoya N, Sakurada M, Kiyokawa H, Nishioka K. Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. Vox Sang 2003 84 : 287 91.
13. Ohtaki M, Satoh K, Kanda T, Fujikoshi Y. Local ridge estimate using random coefficient curve models for analyzing repeated measurements. J Jpn Stat Soc 2007 36 : 177 84.
14. Vonesh EF, Carter RL. Efficient inference for random-coefficient growth curve models with unbalanced data. Biometrics 1987 80 : 642 50.
15. Katayama K, Kumagai J, Komiya Y, Mizui M, Yugi H, Kishimoto S, Yamanaka R, Tamatsukuri S, Tomoguri T, Miyakawa Y, Tanaka J, Yoshizawa H. Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission. Intervirology 2004 47 : 57 64.
16. Tanaka J, Katayama K, Kumagai J, Komiya Y, Yugi H, Kishimoto S, Mizui M, Tomoguri T, Miyakawa Y, Yoshizawa H. Early dynamics of hepatitis C virus in the circulation of chimpanzees with experimental infection. Intervirology 2005 48 : 120 3.
17. Berninger M, Hammer M, Hoyer B, Gerin JL. An assay for the detection of the DNA genome of hepatitis B virus in serum. J Med Virol 1982 9 : 57 68.
18. Ulrich PP, Bhat RA, Seto B, Mack D, Sninski. J, Vyas GN. Enzymatic amplification of hepatitis B virus DNA in serum compared with infectivity testing in chimpanzees. J Infect Dis 1989 160 : 37 43.
19. Prince AM, Stephan W, Brotman B. Beta-propiolactone/ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives. Rev Infect Dis 1983 5 : 92 107.
20. Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MY. Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion 2006 46 : 1829 35.
21. Barker LF, Murray R. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. Am J Med Sci 1972 263 : 27 33.
22. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006 44 : 915 24.